Healthcare & Life Sciences

Context Therapeutics

aliveseries-c-plus
series-c-plus
Stage
1
Investors

About

Context Therapeutics develops clinical-stage bispecific T cell engager antibody therapies targeting solid tumors to activate the immune system for cancer treatment.

Explore Context Therapeutics's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.